The Efficiency and Safety of Mirabegron Monotherapy for the Treatment of Urge Incontinence in Women Aged >80 Years
- PMID: 36793804
- PMCID: PMC9924700
- DOI: 10.7759/cureus.33685
The Efficiency and Safety of Mirabegron Monotherapy for the Treatment of Urge Incontinence in Women Aged >80 Years
Abstract
Objective We aimed to evaluate the efficacy and safety of mirabegron monotherapy in very older (>80 years) women with overactive bladder (OAB) who were discontinued anticholinergic drugs by the other departments. Material and methods The present retrospective study evaluated very older (>80 years) women with OAB who were discontinued anticholinergic drugs by the other departments between May 2018 and January 2021. Efficacy assessments were performed using Overactive Bladder-Validated Eight-Question (OAB-V8) scores before and after mirabegron monotherapy (12 weeks). Safety was evaluated based on adverse events (hypertension, nasopharyngitis, and urinary tract infection), electrocardiography, hypertension measure, uroflowmetry (UFM), and post-voiding. Patient data including demographic characteristics, diagnoses, values before and after mirabegron monotherapy, and adverse events were evaluated. Results A total of 42 very older (>80 years) women with OAB who used mirabegron monotherapy (50 mg per day) were included in this study. Frequency, nocturia, urgency, and total OAB-V8 scores were significantly lower after mirabegron monotherapy than before mirabegron monotherapy (p < 0.05, p < 0.05, p < 0.05, and p < 0.05, respectively). There was no significant difference between systolic-diastolic blood pressure and heart rate before and after mirabegron monotherapy treatment. Conclusion Mirabegron monotherapy is an effective and safe therapy in very older (>80 years) women with OAB.
Keywords: drug side effect; elderly population; mirabegron; urge incontinence; women.
Copyright © 2023, Özcan et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).BJU Int. 2017 Oct;120(4):562-575. doi: 10.1111/bju.13882. Epub 2017 Jun 8. BJU Int. 2017. PMID: 28418102 Clinical Trial.
-
Therapeutic effectiveness and adverse drug reactions of mirabegron versus solifenacin in the treatment of overactive bladder syndrome.Perspect Clin Res. 2024 Jul-Sep;15(3):147-151. doi: 10.4103/picr.picr_166_23. Epub 2024 May 16. Perspect Clin Res. 2024. PMID: 39140022 Free PMC article.
-
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.Eur Urol. 2020 Jan;77(1):119-128. doi: 10.1016/j.eururo.2019.09.024. Epub 2019 Oct 18. Eur Urol. 2020. PMID: 31635815 Clinical Trial.
-
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. Epub 2013 Oct 11. Neurourol Urodyn. 2014. PMID: 24127366 Review.
-
[The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].Ginekol Pol. 2014 Mar;85(3):214-9. doi: 10.17772/gp/1716. Ginekol Pol. 2014. PMID: 24783434 Review. Polish.
References
-
- The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Abrams P, Cardozo L, Fall M, et al. Am J Obstet Gynecol. 2002;187:116–126. - PubMed
-
- Management of urinary incontinence in women: scientific review. Holroyd-Leduc JM, Straus SE. JAMA. 2004;291:986–995. - PubMed
-
- Urinary incontinence and age at the first and last delivery: the Norwegian HUNT/EPINCONT study. Rortveit G, Hunskaar S. Am J Obstet Gynecol. 2006;195:433–438. - PubMed
-
- Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. J Urol. 2015;193:1572–1580. - PubMed
-
- The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Cui Y, Zong H, Yang C, Yan H, Zhang Y. Int Urol Nephrol. 2014;46:275–284. - PubMed
LinkOut - more resources
Full Text Sources